Already 3,824 people have seen this company's branding and they are being followed by 22 Storybook user.In average the company has been rated 4.6 points ja kommenteeritud 15 korda.

's activity report 2022

AS Magnum Veterinaaria is engaged in the wholesale of veterinary medicines, instruments, feed additives and pet products.

AS Magnum Veterinaaria has subsidiaries in Estonia, Latvia and Lithuania. In addition to the Baltic countries, the company was represented by Magnum Veterinaaria

UAB sales representatives also in Belarus, which was immediately discontinued after the start of Russian aggression in Ukraine.

The overall macroeconomic development of the operating environment is positive. The market for pet medicines and other supportive products is stable and the market is in a continuous growth trend. The growing pet product market and the continuous expansion of the product portfolio are the basis for the sales revenue growth of AS

Magnum Veterinaaria.

In the opinion of the management, despite the changed economic environment, the company's credit risk has not significantly changed compared to the past.

The company carefully monitors the payment behavior and financial condition of its customers in order to respond operationally and reduce risks if necessary.

In the opinion of the management, the company's liquidity risk is low and it is able to fulfill its obligations to creditors.

The Management Board estimates that the risks associated with changes in exchange rates and interest rates during the reporting year are insignificant and no transactions were concluded to hedge possible currency risks and interest rate risks.

In addition to direct business objectives, the company also pays attention to environmental friendliness, innovation, contribution to society and employee development, and modern principles of equal treatment of the workforce.

Revenues, expenses and profit

The total turnover of AS Magnum Veterinaaria for the period 01.05.2022-30.04.2023 was 26,216 thousand euros and increased by 13%, (01.05.2021-30.04.2022: 23,171 thousand euros) and the net profit was 1,398 thousand euros (2021/22: 1,477 thousand euros).

Subsidiaries

The sales turnover of the Estonian subsidiary Pet City OÜ for the year 2022/23 amounted to 11,651 thousand euros (2021/22: 10,696 thousand euros).

The net loss was 296 thousand euros (2021/22: 357 thousand euros).

The sales turnover of the Estonian subsidiary Eesti Veterinaaria Kliinikum OÜ for the year 2022/23 amounted to 4,511 thousand euros (2021/22: 4,034 thousand euros). The net loss was 697 thousand euros (2021/22: 467 thousand euros).

The sales turnover of the Latvian subsidiary Magnum Veterinarija SIA for the year 2022/23 amounted to 10,094 thousand euros (2021/22: 8,654 thousand euros).

The net profit was 532 thousand euros (2021/22: 576 thousand euros).

The sales turnover of the Lithuanian subsidiary Magnum Veterinarija UAB for the year 2022/23 amounted to 13,723 thousand euros (20210/22: 11,925 thousand euros). The net profit was 220 thousand euros (2021/22: 191 thousand euros).

Taking into account the significant turnover growth of the subsidiaries due to rapid expansion and the growth of the pet business, we do not currently consider the risk of a decrease in the value of investments to be high and we believe that the value of investments is equal to or higher than their acquisition cost.

Company's financial indicators and ratios